<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Data from the annual survey on transplant activity 1997, collected from 457 transplant teams in 31 European countries by the European Group for Blood and Marrow Transplantation (EBMT) were used to describe current status and to assess relative and absolute changes in indication, donor type and stem cell source compared to 1991 </plain></SENT>
<SENT sid="1" pm="."><plain>A total of 16950 patients were reported to have a first blood or marrow transplant in 1997, a total of 18 923 procedures, including re- and double transplants were performed </plain></SENT>
<SENT sid="2" pm="."><plain>Of the 16950 first transplants, 4751 (28%) were allogeneic, 12199 (72%) autologous transplants </plain></SENT>
<SENT sid="3" pm="."><plain>Of the autologous transplants, 829 (7%) were bone marrow derived, 11370 (93%) from peripheral blood stem cells or combined bone marrow and peripheral blood stem cell transplants </plain></SENT>
<SENT sid="4" pm="."><plain>Of the allogeneic transplants, 3311 (70%) were bone marrow, 1440 (30%) were peripheral blood stem cell transplants </plain></SENT>
<SENT sid="5" pm="."><plain>In 1991, the respective figures were 2175 allogeneic (44%) and 2786 (56%) autologous transplants, more than 90% of the autologous, <z:hpo ids='HP_0000001'>all</z:hpo> allogeneic transplants bone marrow derived </plain></SENT>
<SENT sid="6" pm="."><plain>Main indications in 1997 were <z:hpo ids='HP_0001909'>leukemias</z:hpo> with 5253 transplants (31%), 70% allogeneic; <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with 6773 transplants (40%), 94% autologous; <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> with 4154 transplants (24%), 99% autologous; non-malignant disorders with 770 transplants (5 %), 85 % allogeneic </plain></SENT>
<SENT sid="7" pm="."><plain>There was an absolute increase of 11971 transplants since 1991 </plain></SENT>
<SENT sid="8" pm="."><plain>An increase was observed in <z:hpo ids='HP_0000001'>all</z:hpo> disease categories </plain></SENT>
<SENT sid="9" pm="."><plain>Marked differences were found, when the relative increase index (RII) for specific disease categories over time was analyzed </plain></SENT>
<SENT sid="10" pm="."><plain>In allogeneic transplants, relatively more transplants were performed in 1997 for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> beyond 1st complete remission (RII 1.28), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (RII 1.58), <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (RII 1.33) and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (RII 1.58) </plain></SENT>
<SENT sid="11" pm="."><plain>For autologous transplant indications, a high relative increase index was observed in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (RII 3.77), in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (RII 2.12) and <z:mp ids='MP_0002038'>carcinoma</z:mp> of the breast (RII 6.37) with a relative decrease in <z:hpo ids='HP_0001909'>leukemias</z:hpo> (RII 0.39) and certain <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e> such as <z:hpo ids='HP_0009733'>glioma</z:hpo> (RII 0.27) and <z:hpo ids='HP_0003006'>neuroblastoma</z:hpo> (RII 0.46) </plain></SENT>
<SENT sid="12" pm="."><plain>These data present the current status of blood and marrow transplantation in Europe </plain></SENT>
<SENT sid="13" pm="."><plain>They show the change from bone marrow to blood as stem cell source and highlight shifts in indication </plain></SENT>
<SENT sid="14" pm="."><plain>They provide a basis for patient counselling and health care planning </plain></SENT>
</text></document>